CL2024002576A1 - Derivados heterocíclicos medio o macrocíclicos sustituidos con bencilo y usos relacionados - Google Patents

Derivados heterocíclicos medio o macrocíclicos sustituidos con bencilo y usos relacionados

Info

Publication number
CL2024002576A1
CL2024002576A1 CL2024002576A CL2024002576A CL2024002576A1 CL 2024002576 A1 CL2024002576 A1 CL 2024002576A1 CL 2024002576 A CL2024002576 A CL 2024002576A CL 2024002576 A CL2024002576 A CL 2024002576A CL 2024002576 A1 CL2024002576 A1 CL 2024002576A1
Authority
CL
Chile
Prior art keywords
disorder
macro
medium
substituted heterocycle
related uses
Prior art date
Application number
CL2024002576A
Other languages
English (en)
Spanish (es)
Inventor
R Ott Gregory
GIBSON Karl
Lefker Bruce
Humphries Paul
SPENDIFF Matthew
Original Assignee
Centessa Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centessa Pharmaceuticals Uk Ltd filed Critical Centessa Pharmaceuticals Uk Ltd
Publication of CL2024002576A1 publication Critical patent/CL2024002576A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2024002576A 2022-03-01 2024-08-29 Derivados heterocíclicos medio o macrocíclicos sustituidos con bencilo y usos relacionados CL2024002576A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263315438P 2022-03-01 2022-03-01
US202363439477P 2023-01-17 2023-01-17

Publications (1)

Publication Number Publication Date
CL2024002576A1 true CL2024002576A1 (es) 2025-01-10

Family

ID=85772026

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002576A CL2024002576A1 (es) 2022-03-01 2024-08-29 Derivados heterocíclicos medio o macrocíclicos sustituidos con bencilo y usos relacionados

Country Status (12)

Country Link
US (2) US20250236629A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486748A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025507852A (cg-RX-API-DMAC7.html)
KR (1) KR20240157067A (cg-RX-API-DMAC7.html)
CN (1) CN119110802A (cg-RX-API-DMAC7.html)
AU (1) AU2023228830A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245204A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002576A1 (cg-RX-API-DMAC7.html)
IL (1) IL315237A (cg-RX-API-DMAC7.html)
MX (1) MX2024010608A (cg-RX-API-DMAC7.html)
TW (1) TW202400606A (cg-RX-API-DMAC7.html)
WO (1) WO2023167925A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
EP4680611A1 (en) 2023-03-16 2026-01-21 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
JP2026518313A (ja) 2023-06-01 2026-06-04 ハー・ルンドベック・アクチエゼルスカベット スピロ大環状オレキシン2受容体アゴニスト
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
US20260144795A1 (en) 2024-11-27 2026-05-28 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US10428023B2 (en) 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
PE20211700A1 (es) 2019-01-31 2021-09-01 Takeda Pharmaceuticals Co Compuesto heterociclico y su uso
KR20260083444A (ko) * 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
CN116635393A (zh) * 2020-09-03 2023-08-22 欧瑞夏治疗有限公司 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途

Also Published As

Publication number Publication date
KR20240157067A (ko) 2024-10-31
TW202400606A (zh) 2024-01-01
US20250289828A1 (en) 2025-09-18
JP2025507852A (ja) 2025-03-21
MX2024010608A (es) 2024-09-23
EP4486748A1 (en) 2025-01-08
AU2023228830A1 (en) 2024-09-12
CA3245204A1 (en) 2023-09-07
CN119110802A (zh) 2024-12-10
US20250236629A1 (en) 2025-07-24
WO2023167925A1 (en) 2023-09-07
IL315237A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
MX2024010608A (es) Derivados heterociclicos medio o macrociclicos sustituidos con bencilo y usos relacionados.
WO2022051596A8 (en) Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
ECSP21080740A (es) Inhibidores del inflamasoma nlrp3
DOP2023000168A (es) Compuestos antivirales que contienen nitrilo
CO2022015930A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
CO6251367A2 (es) Derivados de 6-amino-5-aril piridina-2il-carboxamida
CO2022014160A2 (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con la modulación de p13k
CO2022012476A2 (es) Hidrato cristalino de un compuesto inhibidor de jak
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
CL2022003041A1 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
AR128931A1 (es) Inhibidores del factor b del complemento y usos de los mismos
CL2024003450A1 (es) Compuestos y usos de estos
UY39559A (es) Compuestos y su uso
MX2019007071A (es) Novedosos derivados del acido fenilpropionico y usos de los mismos.
AR067538A1 (es) Inhibidortes de la 11 beta -hidroxiesteroide-deshidrogenasa
NI201100137A (es) Derivados de sulfonamida
CU24327B1 (es) Derivados de 1,4-benzotiazepina, útiles para tratar trastornos y enfermedades asociadas con los receptores de rianodina, y las composiciones farmacéuticas que les comprenden
AR127470A1 (es) Inhibidores de lrrk2
MX2023013987A (es) Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
MX2024006975A (es) Inhibidor de cdk9 y uso del mismo.
DOP2025000013A (es) Inhibidores de inflamasoma nlrp3
AR133953A1 (es) Inhibidores del factor b del complemento y usos de los mismos
MX2022005843A (es) Derivados de bencilamida como inhibidores del receptor i del factor de crecimiento transformante beta/ cinasa similar al receptor de activina 5 (alk5).
AR131263A1 (es) Compuestos de pirrolil-sulfonamida fusionados
MX2023011518A (es) Compuestos heterocíclicos novedosos y sus usos.